Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases.

Yang J, Zhang L, Yu C, Yang XF, Wang H. · 2014

Read Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. by Yang J, Zhang L, Yu C, Yang XF, Wang H. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3892095.txt.

Introduction

Jiyeon Yang, Lixiao Zhang, Caijia Yu, Xiao-Feng Yang, and Hong Wang review monocyte types in Biomarker Research, with the record dated 2014. Monocytes are blood immune cells that sense their surroundings and can mature into macrophages or dendritic cells. They come in mixed subsets that shift with local cues.

Rising monocyte counts can flag inflammatory disease. Some subsets fan inflammation while others calm it, and on reaching damaged tissue they mature into local defenders. The review sums what is known of human and mouse subsets and the paths that steer their fate. It stresses the inflammatory subset as a blood marker for diseases such as heart and vessel disease, where an early read could guide care.

Catalog record

CREATORYang J, Zhang L, Yu C, Yang XF, Wang H.
YEAR2014
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3892095

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases By Jiyeon Yang, Lixiao Zhang, Caijia Yu, Xiao-Feng Yang, Hong Wang Published in: Biomarker Research DOI: 10.1186/2050-7771-2-1 ABSTRACT Monocytes express various receptors, which monitor and sense environmental changes. Monocytes are highly plastic and heterogeneous, and change their functional phenotype in response to environmental stimulation. Evidence from murine and human studies has suggested that monocytosis can be an indicator of various inflammatory diseases. Monocytes can differentiate into inflammatory or anti-inflammatory subsets. Upon tissue damage or infection, monocytes are rapidly recruited to the tissue, where they can differentiate into tissue macrophages or dendritic cells. Given the rapid progress in monocyte research from broad spectrum of inflammatory diseases, there is a need to summarize our knowledge in monocyte heterogeneity and its impact in human disease. In this review, we describe the current understanding of heterogeneity of human and murine monocytes, the function of distinct subsets of monocytes, and a potential mechanism for monocyte differentiation. We emphasize that inflammatory monocyte subsets are valuable biomarkers for inflammatory diseases, including cardiovascular diseases. INTRODUCTION The primary role of monocytes was considered to sense the environment and replenish the pool of tissue macrophages and dendritic cells. Recent advances in immunology research have discovered that monocytes are heterogenic and can be divided into three subsets based on specific surface markers and that each subset displays specific functions. During steady state, circulating monocytes have a half-life of about one to three days, and maintain a steady composition of monocyte subsets. Identified monocyte subsets exhibit distinct pathophysiological roles. Classical inflammatory monocytes are equipped with a set of Toll-like receptors (TLRs) and scavenger receptors, recognizing pathogen-associated molecular patterns (PAMPs) and removing microorganisms, lipids, and dying cells via phagocytosis. They produce effector molecules such as cytokines, myeloperoxidase and superoxide, and initiate inflammation [1]. Inflammatory monocytes selectively traffic to the sites of inflammation, produce inflammatory cytokines and contribute to local and systemic inflammation [2]. They are highly infiltrative and can be differentiated into inflammatory macrophages, which remove PAMPs and cell debris. In steady state, the patrolling anti-inflammatory monocytes patrol the vasculature to monitor PAMPs and become tissue resident macrophages. During inflammation, they differentiate into anti-inflammatory macrophages, which repair damaged tissues [3]. Murine monocyte subset classification and their functional determinations have been consistent and well accepted [4]. However, classification of human monocyte subsets in relevance to their inflammatory or anti-inflammatory functional phenotypes remains partially undefined. Here, we intend to review the current understanding regarding monocyte heterogeneity, and to integrate the knowledge of murine and human monocyte classification. Monocytosis and heterogeneous monocytes It was first reported in the 1970s that monocytes increase proliferative activity in bone marrow (BM) in response to inflammatory stimuli, leading to monocytosis, [5] a clinical condition reflecting an increased number of circulating monocytes. Emerging clinical analysis revealed a higher prevalence of monocytosis in cardiovascular diseases (CVD) (Table 1). Monocyte count is increased in acute myocardial infarction (AMI) patients compared to patients with stable coronary arterial disease (CAD) [6]. Peripheral monocytosis is associated with left ventricular (LV) dysfunction and LV aneurysm, suggesting a possible role of monocytes in the development of LV remodeling after reperfused AMI [7]. Monocytosis is also associated with reduced high-density lipoprotein (HDL) levels and impaired renal function in CAD patients [8]. It has been demonstrated that monocyte count is a better independent risk factor of CVD than several conventional risk factors such as C-reactive protein (CRP), inflammatory cytokine interleukin-6 (IL-6), fibrinogen, hypertension, and cigarette smoking [9]. The treatment of coronary arterial disease patients with pravastatin, a cholesterol lowering medication, for 6 months reduces plaque volume and monocyte count, implying that monocytosis is a potential target for coronary atherosclerotic regression [10]. [Table: Monocytosis in human disease] Following the defining of monocytosis, reduced phagocytic capacity of monocytes was found in patients with rheumatoid arthritis and cutaneous vasculitis [11]. Patients with lymphopenia have suppressor monocytes, which are unable to activate T-cells [12]. These findings suggested the existence of heterogeneous monocyte populations. Further studies for different functional properties of such populations identified that CD16 (Leu-11), a Fc receptor (FcR) as it binds to the Fc region (constant region) of antibody, is expressed on the surface of monocytes and correlated with atherosclerosis and CVD in patients and an inflammatory phenotype in cultured monocytes and circulating monocytes [13]. The CD16+ monocytes has been considered an inflammatory monocyte subset in humans [14]. Mouse monocyte subsets Monocyte subsets in mice were first identified by differential expression of chemokine receptors CCR2. CCR2+ subset shows higher migratory and infiltration capacity than CCR2- subset and was initially considered as murine inflammatory monocyte [15]. Later on, mouse monocyte subsets are characterized by differential expression of an inflammatory monocyte marker Ly6C (Gr1). It is now accepted that mouse monocyte subsets are grouped as Ly6C+ (further divided as Ly6Chigh + Ly6Cmiddle) and Ly6C- (also called Ly6Clow) monocyte subsets based on expression levels of Ly6C on cell surface (Table 2). The surface markers and chemokine receptors for Ly6C+ subsets are CD11b+CD115+ and CCR2highCX3CR1low. Whereas, the surface markers and chemokine receptors for Ly6C- monocytes are CD11b+CD115+ and CCR2lowCX3CR1high[16]. [Table: Markers and functions of MC subsets in human and mouse] Functional properties of mouse monocyte subsets As shown in Figure 1, mouse Ly6C+ monocytes have a high antimicrobial capability due to their potent capacity for phagocytosis, secrete ROS, TNFα, nitric oxide, IL-1β, little IL-10 upon bacterial infection [17] and large amount of type 1 interferon (IFN) in response to viral ligands [18]. CCR2-CCL2 signaling in Ly6C+ monocytes alters the conformational change of VLA-4 (α4β1 integrin), the ligand for VCAM-1, leading to high affinity interaction and monocyte transmigration (Figure 1). In vascular inflammation, Ly6C+ monocytes are preferentially recruited into inflamed tissue via interaction of chemokine receptor CCR2 [19] and more likely to mature to inflammatory M1 macrophages, which are distinguished by secretion of pro-inflammatory cytokine, TNFα, and IL-6 and contribute to tissue degradation and T cell activation. [Figure: Human MC and Mϕ differentiation, and distinct subset functions. Human CD14++CD16- classical MCs leave the bone marrow in a CC-chemokine receptor 2 (CCR2)-dependent manner. In the steady state, classical MCs can differentiate into intermediate MCs, then differentiate into patrolling non-classical MCs in circulation. Classical MCs have a high antimicrobial capability due to their potent capacity of phagocytosis, and secrete ROS and IL-10 upon LPS stimulus, whereas intermediate and non-classical MCs secrete inflammatory cytokines, TNFα and IL-1β upon inflammatory stimulation. During inflammation, classical and intermediate MCs are tethered and invade tissue by interaction of complementary pair CCR2/CCL2(MCP1) or/and CCR5/CCL5(RANTES) in a VLA1/VCAM1 dependent manner. MCs then mature to M1Mϕ in tissue and present self-antigen via MHC-I/II to TCR leading to TC activation. Non-classical MCs patrol the vessel wall and invade by interaction of complementary pair of CX3CR1/CCL3 via LAF/ICAM1-dependent manner. TC, T cell; MC, monocyte; Mϕ, macrophage; EC, endothelial cells; inf., inflammatory; α-inf. Anti-inflammatory; TCR, T cell receptor; HLA-DR, human leukocyte antigen DR (a major histocompatibility complex class II (MHC-II)).] In steady state, Ly6C+ monocytes differentiate into Ly6C- monocytes in the circulation. This subset patrols the luminal side of endothelium of small blood vessels and bind to endothelium by chemokine receptor CX3CR1 via LAF-1/ICAM1-dependent manner. The patrolling behavior of monocytes may be due to low levels expression of

Read the complete text